Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant 5-FU Modulation in Rectal Cancer
NCT01060501Phase 3Completed
- Sponsor
- Ulm University
- Start
- Jul 1992
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of folinic acid and interferon alfa in rectal cancer, sponsored by Ulm University. Primary endpoint: Overall Survival at 5 years. Started Jul 1992; status: completed.
02
Drugs
folinic acidinterferon alfa
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01060501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01060501.